var data={"title":"Dientamoeba fragilis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Dientamoeba fragilis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/contributors\" class=\"contributor contributor_credentials\">Peter F Weller, MD, MACP</a></dd><dd><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/contributors\" class=\"contributor contributor_credentials\">Karin Leder, MBBS, FRACP, PhD, MPH, DTMH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/contributors\" class=\"contributor contributor_credentials\">Edward T Ryan, MD, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 02, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Dientamoeba fragilis</em> is an anaerobic intestinal protozoan parasite. Historically, this organism was among a group of enteric protozoan parasites beginning with <em>Giardia duodenalis </em>(previously<em> G. lamblia)</em> that were initially believed to be commensals and not capable of causing symptomatic illness. As more information became available and antimicrobial agents were developed with activity against these parasites, it became clear that <em>D. fragilis</em> can cause an active infection, although it does not always result in symptomatic disease. (See <a href=\"topic.htm?path=giardiasis-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Giardiasis: Epidemiology, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=blastocystis-species\" class=\"medical medical_review\">&quot;Blastocystis species&quot;</a> and <a href=\"topic.htm?path=nonpathogenic-enteric-protozoa\" class=\"medical medical_review\">&quot;Nonpathogenic enteric protozoa&quot;</a>.)</p><p>While the capacity of <em>D. fragilis</em> to cause symptomatic intestinal illness is increasingly recognized, there are a number of uncertainties surrounding <em>D. fragilis</em> [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. In some studies, detection of <em>D. fragilis</em> in stool has been observed more frequently among asymptomatic individuals than among symptomatic patients [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/3,4\" class=\"abstract_t\">3,4</a>]. Moreover, the means by <em>D. fragilis</em> is transmitted has not been fully defined. Finally, the diagnostic recognition of this parasite in stool examinations requires specific processing and expertise; thus, it is possible that many infections may go undiagnosed.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ultrastructural, immunologic, and genetic analyses place <em>D. fragilis</em> in the family of protozoan flagellates, which includes <em>Trichomonas</em> [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/2,5\" class=\"abstract_t\">2,5</a>]. Unlike other intestinal protozoan organisms that have both trophozoite and hardy cyst stages, for a long time <em>D. fragilis</em> was recognized to exist only as trophozoites. Trophozoites measure 7 to 12 micrometers in diameter, contain one or two nuclei, lack flagellae, and are minimally motile. However, cyst forms of <em>D. fragilis</em> have been identified in experimental mouse infections and in human fecal samples [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/6\" class=\"abstract_t\">6</a>], suggesting that cystic forms are the transmissible infectious form of this organism.</p><p>There is genetic evidence for at least two variants of <em>D. fragilis</em>. However, it is unknown if these two differ in their pathogenicity [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/7\" class=\"abstract_t\">7</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infections with <em>D. fragilis</em> are acquired by the fecal-oral route, but how fragile trophozoites survive outside of the body and do not succumb to stomach acid following ingestion are not fully understood (<a href=\"image.htm?imageKey=ID%2F75072\" class=\"graphic graphic_figure graphicRef75072 \">figure 1</a>). Some investigators suggested that trophozoites might survive within and be ingested with the eggs of the pinworm <em>Enterobius vermicularis</em>. While this might explain coinfection in some children, it does not likely explain most <em>D. fragilis</em> infections. In addition, some studies have specifically failed to find a correlation between <em>D. fragilis</em> and <em>E. vermicularis </em>infections [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/8\" class=\"abstract_t\">8</a>]. The recognition of cyst forms of the parasite may be important for understanding transmission [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/6\" class=\"abstract_t\">6</a>]. In addition, sheep, pigs, and nonhuman primates have been identified as natural hosts of the genotypes found in humans, suggesting zoonotic potential for human transmission [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"topic.htm?path=enterobiasis-pinworm-and-trichuriasis-whipworm\" class=\"medical medical_review\">&quot;Enterobiasis (pinworm) and trichuriasis (whipworm)&quot;</a>.)</p><p><em>D. fragilis</em> is distributed globally; the prevalence varies with geography [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/10-18\" class=\"abstract_t\">10-18</a>]. In series from different countries, <em>D. fragilis</em> was detected in approximately 5 percent of stool samples submitted for diagnostic examination in the United States and Australia [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/8,10,19\" class=\"abstract_t\">8,10,19</a>], 5 percent in the Sultanate of Oman [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/13\" class=\"abstract_t\">13</a>], and 8 percent in the Netherlands among patients with diarrhea lasting more than a week [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/14\" class=\"abstract_t\">14</a>]. In the United States, <em>D. fragilis</em> has been detected in returned missionaries [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/16\" class=\"abstract_t\">16</a>] and patients with traveler's diarrhea [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/18\" class=\"abstract_t\">18</a>].</p><p>Many diagnostic laboratories lack the requisite procedures to detect <em>D. fragilis, </em>since trophozoites deteriorate rapidly and can therefore be missed by microscopy unless there is prompt fixation of the specimen [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/10,12\" class=\"abstract_t\">10,12</a>]. Thus, the prevalence of <em>D. fragilis</em> is probably underestimated. In a report from Ottawa, Canada, 91 percent of healthy children had detectable serum antibodies to <em>D. fragilis</em>, suggesting that mild or subclinical infections were common during childhood (though cross-reactivity is possible) [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/20\" class=\"abstract_t\">20</a>]. Another report from rural Venezuela noted a 40 percent prevalence of <em>D. fragilis</em> with use of combined microscopy&ndash;polymerase chain reaction (compared with 16 percent for microscopy alone) [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/21\" class=\"abstract_t\">21</a>].</p><p>In addition to geography, other factors may favor <em>D. fragilis</em> infection, such as rural residence and pet exposure [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/22\" class=\"abstract_t\">22</a>]. However, the data from different regions are conflicting as to whether infection is more common in females [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/23\" class=\"abstract_t\">23</a>] or males [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/24,25\" class=\"abstract_t\">24,25</a>]. It is also unclear whether or not there is seasonal variation [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/23,25\" class=\"abstract_t\">23,25</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical presentation with <em>D. fragilis</em> is variable; the most common presentation consists of gastrointestinal illnesses. The incubation period prior to the onset of symptoms following infection is unknown, as is the proportion of infected people who remain asymptomatic. The parasite localizes in the colon and can cause colitis [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/26\" class=\"abstract_t\">26</a>]. Common complaints in those who are symptomatic include abdominal pain, flatulence, acute and recurrent diarrhea, or loose stools [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/2,8,11,23,24,26-28\" class=\"abstract_t\">2,8,11,23,24,26-28</a>]. In one review, most patients presented with diarrhea and abdominal pain, frequently lasting longer than a duration of two weeks [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/19\" class=\"abstract_t\">19</a>]. In one study of Turkish patients infected with <em>D. fragilis</em>, symptoms included [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/11\" class=\"abstract_t\">11</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abdominal pain &ndash; 81 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diarrhea &ndash; 72 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anorexia &ndash; 16 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fatigue &ndash; 9 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nausea &ndash; 6 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Weight loss &ndash; 3 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vomiting &ndash; 3 percent</p><p/><p>Abdominal pain and diarrhea presumed to be attributable to <em>D. fragilis</em> infections may persist for several years [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/2,8,11,13,24,27\" class=\"abstract_t\">2,8,11,13,24,27</a>]. <em>D. fragilis</em> infection may be observed in some patients fulfilling criteria for irritable bowel syndrome [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-irritable-bowel-syndrome-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of irritable bowel syndrome in adults&quot;</a>.)</p><p>Children are susceptible to infection with <em>D. fragilis</em> and may present with clinical symptoms (especially diarrhea and abdominal pain) more frequently than adults; they may also have prolonged infection [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/30,31\" class=\"abstract_t\">30,31</a>]. One case-control study among Australian children demonstrated that diarrhea was significantly more common in children with <em>D. fragilis</em> infection than controls [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/32\" class=\"abstract_t\">32</a>]. However, another study of children with chronic abdominal pain noted that abdominal symptoms were not more prevalent among children with <em>D. fragilis</em> [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/33\" class=\"abstract_t\">33</a>].</p><p>Peripheral blood eosinophilia may accompany <em>D. fragilis</em> infections [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/26,27,34\" class=\"abstract_t\">26,27,34</a>], and an eosinophil-enriched colitis due to <em>D. fragilis</em> infection may be mistaken for allergic colitis [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/26\" class=\"abstract_t\">26</a>]. The presence of eosinophilia in this infection is in striking contrast with disease caused by other intestinal protozoa, with the exception of <em>Isospora belli</em> infections. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cystoisospora-isospora-infections\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of Cystoisospora (Isospora) infections&quot;</a> and <a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">&quot;Approach to the patient with unexplained eosinophilia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of <em>D. fragilis</em> traditionally rests with detection of trophozoites in microscopic examinations of fixed and stained stool samples [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/2\" class=\"abstract_t\">2</a>]. Trophozoites are fragile and are not detectable on wet mounts, iodine-stained samples, or formalin-ethyl acetate concentrates [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/11\" class=\"abstract_t\">11</a>]. Thus, fixation of stool samples in polyvinyl alcohol fixative, sodium acetate-acetic acid-formalin fixative, or Schaudinn's fixative is necessary, as is the use of permanent trichrome staining [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/12,28\" class=\"abstract_t\">12,28</a>].</p><p>Giemsa-stained stool smears may be helpful in detecting <em>D. fragilis</em> [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/30\" class=\"abstract_t\">30</a>]. There are no available <em>D. fragilis</em> immunofluorescent or antigen assays that can be used in lieu of conventional microscopic evaluation. Specific cultivation methods have been shown effective in the detection of <em>D. fragilis</em> in stool but are not commonly available [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/2,35,36\" class=\"abstract_t\">2,35,36</a>].</p><p>Conventional and real-time polymerase chain reaction (PCR) methods have been developed that have significantly higher sensitivity and specificity than microscopy [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/2,37-41\" class=\"abstract_t\">2,37-41</a>]. PCR-based assays have been developed to concurrently detect <em>D. fragilis</em> as well as <em>Blastocystis</em>, <em>Cryptosporidium</em>, <em>Giardia</em>, and <em>Entamoeba</em> in human stool samples [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/42\" class=\"abstract_t\">42</a>].</p><p>Laboratories that optimally fix and stain stools have substantially higher yields in detecting <em>D. fragilis</em> infections [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/12\" class=\"abstract_t\">12</a>]. While many infections can be diagnosed with a single stool exam, the ability to confirm <em>D. fragilis</em> trophozoites increases by approximately 30 percent if three serial stool examinations are performed [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/12,43\" class=\"abstract_t\">12,43</a>].</p><p class=\"headingAnchor\" id=\"H1074648100\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gastrointestinal symptoms &ndash; Other protozoal parasites including giardiasis and <em>Blastocystis</em> can cause similar symptoms of abdominal pain, diarrhea, and anorexia. These are distinguished from <em>D. fragilis</em> via stool microscopy, immunoassay, or polymerase chain reaction. (See <a href=\"topic.htm?path=giardiasis-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Giardiasis: Epidemiology, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=blastocystis-species\" class=\"medical medical_review\">&quot;Blastocystis species&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gastrointestinal symptoms and eosinophilia &ndash; Other causes of gastrointestinal symptoms and eosinophilia include isosporiasis, strongyloidiasis, ascariasis, and hookworm. Coinfection can occur; the diagnoses are distinguished by stool microscopy. (See <a href=\"topic.htm?path=strongyloidiasis\" class=\"medical medical_review\">&quot;Strongyloidiasis&quot;</a> and <a href=\"topic.htm?path=ascariasis\" class=\"medical medical_review\">&quot;Ascariasis&quot;</a> and <a href=\"topic.htm?path=hookworm-infection\" class=\"medical medical_review\">&quot;Hookworm infection&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Irritable bowel syndrome &ndash; Clinical manifestations of irritable bowel syndrome include chronic abdominal pain and altered bowel habits, including diarrhea or constipation. The diagnosis is established based on clinical criteria. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-irritable-bowel-syndrome-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of irritable bowel syndrome in adults&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H21483355\"><span class=\"h2\">Clinical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infections with <em>D. fragilis</em> should be treated when the organism is found as a sole pathogen in stool samples from patients with abdominal pain or diarrhea lasting for more than one week.</p><p>No large-scale randomized controlled trials have been performed to assess the effect of various antimicrobial agents in patients infected with <em>D. fragilis</em> [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/44\" class=\"abstract_t\">44</a>]. There are several regimens that may be used to treat <em>D. fragilis</em> infections, including [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/27,31,45,46\" class=\"abstract_t\">27,31,45,46</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">Metronidazole</a> (500 to 750 mg three times a day for 10 days)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">Paromomycin</a> (25 to 35 <span class=\"nowrap\">mg/kg</span> per day in three divided doses for 7 days)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=iodoquinol-drug-information\" class=\"drug drug_general\">Iodoquinol</a> (650 mg three times a day for 20 days)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">Tetracycline</a> (500 mg [10 <span class=\"nowrap\">mg/kg]</span> orally four times daily for 10 days) or <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> (100 mg [2 <span class=\"nowrap\">mg/kg]</span> orally twice daily for 10 days)</p><p/><p>In a study evaluating the in vitro susceptibility of <em>D. fragilis</em> to several antiparasitic agents, 5-nitroimidazole derivatives were found to be the most active compounds (including ornidazole, <a href=\"topic.htm?path=tinidazole-drug-information\" class=\"drug drug_general\">tinidazole</a>, <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>, and <a href=\"topic.htm?path=secnidazole-drug-information\" class=\"drug drug_general\">secnidazole</a>), followed by <a href=\"topic.htm?path=nitazoxanide-drug-information\" class=\"drug drug_general\">nitazoxanide</a>, tetracyclines, furazolidone, <a href=\"topic.htm?path=iodoquinol-drug-information\" class=\"drug drug_general\">iodoquinol</a>, <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a>, and diloxanide furoate [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/47\" class=\"abstract_t\">47</a>]. Benzimidazoles (<a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">albendazole</a>, <a href=\"topic.htm?path=mebendazole-drug-information\" class=\"drug drug_general\">mebendazole</a>) have no activity in vitro against <em>D. fragilis </em>[<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/48\" class=\"abstract_t\">48</a>].</p><p>Another study included 96 children with <em>D. fragilis</em> infection and chronic gastrointestinal symptoms treated with a 10-day course of <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> or placebo; eradication of <em>D. fragilis</em> was significantly greater in the metronidazole group as assessed by polymerase chain reaction (PCR) 14 days after completion of therapy, although PCR positivity rebounded by eight weeks after completion of therapy to levels comparable with those seen in placebo recipients [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/49\" class=\"abstract_t\">49</a>]. Change in gastrointestinal symptoms following treatment did not differ significantly between the groups.</p><p>Data suggest <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> is efficacious despite relatively weak in vitro susceptibility data as well as a lack of randomized controlled trial data [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/19,50\" class=\"abstract_t\">19,50</a>]; one report noted eradication rates of 98 percent [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/51\" class=\"abstract_t\">51</a>].</p><p><a href=\"topic.htm?path=iodoquinol-drug-information\" class=\"drug drug_general\">Iodoquinol</a> has traditionally been used quite commonly, but its availability is declining.</p><p class=\"headingAnchor\" id=\"H1058301631\"><span class=\"h2\">Other agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>, other nitroimidazole agents with potential efficacy include <a href=\"topic.htm?path=secnidazole-drug-information\" class=\"drug drug_general\">secnidazole</a>, ornidazole, and <a href=\"topic.htm?path=tinidazole-drug-information\" class=\"drug drug_general\">tinidazole</a>.</p><p><a href=\"topic.htm?path=secnidazole-drug-information\" class=\"drug drug_general\">Secnidazole</a> was evaluated in a study of 35 Turkish patients with <em>D. fragilis</em> infection; in all but one patient, the organism was eradicated with a single dose of secnidazole, suggesting that secnidazole is effective in achieving parasitological and clinical cure [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/11\" class=\"abstract_t\">11</a>].</p><p>Ornidazole (30 <span class=\"nowrap\">mg/kg</span> single dose for children and 2 g single dose for adults) was superior to <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> in a randomized trial of 112 Turkish patients with respect to parasitologic cure (92.9 versus 69.6 percent, p = 0.001) and clinical cure (96.4 versus 76.8 percent, p = 0.001) [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/52\" class=\"abstract_t\">52</a>].</p><p><a href=\"topic.htm?path=tinidazole-drug-information\" class=\"drug drug_general\">Tinidazole</a> (2 g single dose) is more widely available than the above agents and is better tolerated than <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>; use of this agent is reasonable although data are limited. It may be effective in combination with <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> or other agents; further study is needed [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/19,50\" class=\"abstract_t\">19,50</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since the mechanism of <em>D. fragilis</em> transmission is not fully understood, there are no specific guidelines on measures to prevent acquisition of infection with this organism. Screening of household members of <em>D. fragilis</em> patients has been suggested [<a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/34,53\" class=\"abstract_t\">34,53</a>], especially in cases of relapsed infection.</p><p class=\"headingAnchor\" id=\"H18561528\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Dientamoeba fragilis</em> is an anaerobic intestinal protozoan parasite. It is a flagellate that produces trophozoites as well as cysts. Infection may be symptomatic or asymptomatic. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H2\" class=\"local\">'Microbiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infection is transmitted by the fecal-oral route. <em>D. fragilis</em> is distributed globally but the prevalence varies with geography. Since many diagnostic laboratories lack the requisite procedures for detection, the prevalence is probably underestimated. (See <a href=\"#H3\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The incubation period and proportion of asymptomatic infected individuals are unknown. The parasite localizes in the colon and can cause colitis. Common symptoms include abdominal pain and acute and recurrent diarrhea. <em>D. fragilis</em> may present with peripheral eosinophilia <span class=\"nowrap\">and/or</span> eosinophilic colitis. (See <a href=\"#H4\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis is made via detection of <em>D. fragilis</em> trophozoites in microscopic examinations of appropriately fixed and stained stool samples or by polymerase chain reaction&ndash;based techniques. (See <a href=\"#H5\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment is warranted when the organism is found as a sole pathogen in stool samples in the setting of abdominal pain or diarrhea lasting more than one week. The optimal therapy is uncertain; we suggest treatment with <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> or <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H6\" class=\"local\">'Treatment'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/1\" class=\"nounderline abstract_t\">Weiss LM, Keohane EM. The uncommon gastrointestinal Protozoa: Microsporidia, Blastocystis, Isospora, Dientamoeba, and Balantidium. Curr Clin Top Infect Dis 1997; 17:147.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/2\" class=\"nounderline abstract_t\">Johnson EH, Windsor JJ, Clark CG. Emerging from obscurity: biological, clinical, and diagnostic aspects of Dientamoeba fragilis. Clin Microbiol Rev 2004; 17:553.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/3\" class=\"nounderline abstract_t\">Krogsgaard LR, Engsbro AL, Stensvold CR, et al. The prevalence of intestinal parasites is not greater among individuals with irritable bowel syndrome: a population-based case-control study. Clin Gastroenterol Hepatol 2015; 13:507.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/4\" class=\"nounderline abstract_t\">Bruijnesteijn van Coppenraet LE, Dullaert-de Boer M, Ruijs GJ, et al. Case-control comparison of bacterial and protozoan microorganisms associated with gastroenteritis: application of molecular detection. Clin Microbiol Infect 2015; 21:592.e9.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/5\" class=\"nounderline abstract_t\">Silberman JD, Clark CG, Sogin ML. Dientamoeba fragilis shares a recent common evolutionary history with the trichomonads. Mol Biochem Parasitol 1996; 76:311.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/6\" class=\"nounderline abstract_t\">Stark D, Garcia LS, Barratt JL, et al. Description of Dientamoeba fragilis cyst and precystic forms from human samples. J Clin Microbiol 2014; 52:2680.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/7\" class=\"nounderline abstract_t\">Johnson JA, Clark CG. Cryptic genetic diversity in Dientamoeba fragilis. J Clin Microbiol 2000; 38:4653.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/8\" class=\"nounderline abstract_t\">Stark D, Beebe N, Marriott D, et al. Prospective study of the prevalence, genotyping, and clinical relevance of Dientamoeba fragilis infections in an Australian population. J Clin Microbiol 2005; 43:2718.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/9\" class=\"nounderline abstract_t\">Cacci&ograve; SM, Sannella AR, Manuali E, et al. Pigs as natural hosts of Dientamoeba fragilis genotypes found in humans. Emerg Infect Dis 2012; 18:838.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/10\" class=\"nounderline abstract_t\">Kappus KD, Lundgren RG Jr, Juranek DD, et al. Intestinal parasitism in the United States: update on a continuing problem. Am J Trop Med Hyg 1994; 50:705.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/11\" class=\"nounderline abstract_t\">Girginkarde&#351;ler N, Co&#351;kun S, C&uuml;neyt Balcio&#287;lu I, et al. Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole. Clin Microbiol Infect 2003; 9:110.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/12\" class=\"nounderline abstract_t\">Grendon JH, Digiacomo RF, Frost FJ. Dientamoeba fragilis detection methods and prevalence: a survey of state public health laboratories. Public Health Rep 1991; 106:322.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/13\" class=\"nounderline abstract_t\">Windsor JJ, Rafay AM, Shenoy AK, Johnson EH. Incidence of Dientamoeba fragilis in faecal samples submitted for routine microbiological analysis. Br J Biomed Sci 1998; 55:172.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/14\" class=\"nounderline abstract_t\">van Gool T, Dankert J. [3 emerging protozoal infections in The Netherlands: Cyclospora, Dientamoeba, and Microspora infections]. Ned Tijdschr Geneeskd 1996; 140:155.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/15\" class=\"nounderline abstract_t\">Oyofo BA, Peruski LF, Ismail TF, et al. Enteropathogens associated with diarrhea among military personnel during Operation Bright Star 96, in Alexandria, Egypt. Mil Med 1997; 162:396.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/16\" class=\"nounderline abstract_t\">McQuay RM. Parasitologic studies in a group of furloughed missionaries. I. Intestinal protozoa. Am J Trop Med Hyg 1967; 16:154.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/17\" class=\"nounderline abstract_t\">Millet VE, Spencer MJ, Chapin MR, et al. Intestinal protozoan infection in a semicommunal group. Am J Trop Med Hyg 1983; 32:54.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/18\" class=\"nounderline abstract_t\">Stark D, Beebe N, Marriott D, et al. Dientamoeba fragilis as a cause of travelers' diarrhea: report of seven cases. J Travel Med 2007; 14:72.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/19\" class=\"nounderline abstract_t\">Stark D, Barratt J, Roberts T, et al. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg 2010; 82:614.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/20\" class=\"nounderline abstract_t\">Chan F, Stewart N, Guan M, et al. Prevalence of Dientamoeba fragilis antibodies in children and recognition of a 39 kDa immunodominant protein antigen of the organism. Eur J Clin Microbiol Infect Dis 1996; 15:950.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/21\" class=\"nounderline abstract_t\">Incani RN, Ferrer E, Hoek D, et al. Diagnosis of intestinal parasites in a rural community of Venezuela: Advantages and disadvantages of using microscopy or RT-PCR. Acta Trop 2017; 167:64.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/22\" class=\"nounderline abstract_t\">Heusinkveld M, Mughini-Gras L, Pijnacker R, et al. Potential causative agents of acute gastroenteritis in households with preschool children: prevalence, risk factors, clinical relevance and household transmission. Eur J Clin Microbiol Infect Dis 2016; 35:1691.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/23\" class=\"nounderline abstract_t\">Grendon JH, DiGiacomo RF, Frost FJ. Descriptive features of Dientamoeba fragilis infections. J Trop Med Hyg 1995; 98:309.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/24\" class=\"nounderline abstract_t\">Norberg A, Nord CE, Eveng&aring;rd B. Dientamoeba fragilis--a protozoal infection which may cause severe bowel distress. Clin Microbiol Infect 2003; 9:65.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/25\" class=\"nounderline abstract_t\">Lagac&eacute;-Wiens PR, VanCaeseele PG, Koschik C. Dientamoeba fragilis: an emerging role in intestinal disease. CMAJ 2006; 175:468.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/26\" class=\"nounderline abstract_t\">Cuffari C, Oligny L, Seidman EG. Dientamoeba fragilis masquerading as allergic colitis. J Pediatr Gastroenterol Nutr 1998; 26:16.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/27\" class=\"nounderline abstract_t\">Preiss U, Ockert G, Broemme S, Otto A. On the clinical importance of Dientamoeba fragilis infections in childhood. J Hyg Epidemiol Microbiol Immunol 1991; 35:27.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/28\" class=\"nounderline abstract_t\">Stark D, Barratt J, Chan D, Ellis JT. Dientamoeba fragilis, the Neglected Trichomonad of the Human Bowel. Clin Microbiol Rev 2016; 29:553.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/29\" class=\"nounderline abstract_t\">Yakoob J, Jafri W, Beg MA, et al. Blastocystis hominis and Dientamoeba fragilis in patients fulfilling irritable bowel syndrome criteria. Parasitol Res 2010; 107:679.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/30\" class=\"nounderline abstract_t\">Crotti D, D'Annibale ML, Fonzo G, et al. Dientamoeba fragilis is more prevalent than Giardia duodenalis in children and adults attending a day care centre in Central Italy. Parasite 2005; 12:165.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/31\" class=\"nounderline abstract_t\">Preiss U, Ockert G, Br&ouml;mme S, Otto A. Dientamoeba fragilis infection, a cause of gastrointestinal symptoms in childhood. Klin Padiatr 1990; 202:120.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/32\" class=\"nounderline abstract_t\">Banik GR, Barratt JL, Marriott D, et al. A case-controlled study of Dientamoeba fragilis infections in children. Parasitology 2011; 138:819.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/33\" class=\"nounderline abstract_t\">de Jong MJ, Korterink JJ, Benninga MA, et al. Dientamoeba fragilis and chronic abdominal pain in children: a case-control study. Arch Dis Child 2014; 99:1109.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/34\" class=\"nounderline abstract_t\">Gray TJ, Kwan YL, Phan T, et al. Dientamoeba fragilis: a family cluster of disease associated with marked peripheral eosinophilia. Clin Infect Dis 2013; 57:845.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/35\" class=\"nounderline abstract_t\">Windsor JJ, Macfarlane L. Irritable bowel syndrome: the need to exclude Dientamoeba fragilis. Am J Trop Med Hyg 2005; 72:501; author reply 501.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/36\" class=\"nounderline abstract_t\">Windsor JJ, Macfarlane L, Hughes-Thapa G, et al. Detection of Dientamoeba fragilis by culture. Br J Biomed Sci 2003; 60:79.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/37\" class=\"nounderline abstract_t\">Stark D, Beebe N, Marriott D, et al. Detection of Dientamoeba fragilis in fresh stool specimens using PCR. Int J Parasitol 2005; 35:57.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/38\" class=\"nounderline abstract_t\">Stark D, Beebe N, Marriott D, et al. Evaluation of three diagnostic methods, including real-time PCR, for detection of Dientamoeba fragilis in stool specimens. J Clin Microbiol 2006; 44:232.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/39\" class=\"nounderline abstract_t\">Stark D, Al-Qassab SE, Barratt JL, et al. Evaluation of multiplex tandem real-time PCR for detection of Cryptosporidium spp., Dientamoeba fragilis, Entamoeba histolytica, and Giardia intestinalis in clinical stool samples. J Clin Microbiol 2011; 49:257.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/40\" class=\"nounderline abstract_t\">Calderaro A, Gorrini C, Montecchini S, et al. Evaluation of a real-time polymerase chain reaction assay for the detection of Dientamoeba fragilis. Diagn Microbiol Infect Dis 2010; 67:239.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/41\" class=\"nounderline abstract_t\">Maas L, Dorigo-Zetsma JW, de Groot CJ, et al. Detection of intestinal protozoa in paediatric patients with gastrointestinal symptoms by multiplex real-time PCR. Clin Microbiol Infect 2014; 20:545.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/42\" class=\"nounderline abstract_t\">Stark D, Roberts T, Ellis JT, et al. Evaluation of the EasyScreen&trade; enteric parasite detection kit for the detection of Blastocystis spp., Cryptosporidium spp., Dientamoeba fragilis, Entamoeba complex, and Giardia intestinalis from clinical stool samples. Diagn Microbiol Infect Dis 2014; 78:149.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/43\" class=\"nounderline abstract_t\">Hiatt RA, Markell EK, Ng E. How many stool examinations are necessary to detect pathogenic intestinal protozoa? Am J Trop Med Hyg 1995; 53:36.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/44\" class=\"nounderline abstract_t\">Stark DJ, Beebe N, Marriott D, et al. Dientamoebiasis: clinical importance and recent advances. Trends Parasitol 2006; 22:92.</a></li><li class=\"breakAll\">Drugs for Parasitic Infections, 3rd Ed, The Medical Letter, New Rochelle, NY 2013.</li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/46\" class=\"nounderline abstract_t\">Nagata N, Marriott D, Harkness J, et al. Current treatment options for Dientamoeba fragilis infections. Int J Parasitol Drugs Drug Resist 2012; 2:204.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/47\" class=\"nounderline abstract_t\">Nagata N, Marriott D, Harkness J, et al. In vitro susceptibility testing of Dientamoeba fragilis. Antimicrob Agents Chemother 2012; 56:487.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/48\" class=\"nounderline abstract_t\">Stark D, Barratt JL, Roberts T, et al. Activity of benzimidazoles against Dientamoeba fragilis (Trichomonadida, Monocercomonadidae) in vitro and correlation of beta-tubulin sequences as an indicator of resistance. Parasite 2014; 21:41.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/49\" class=\"nounderline abstract_t\">R&ouml;ser D, Simonsen J, Stensvold CR, et al. Metronidazole therapy for treating dientamoebiasis in children is not associated with better clinical outcomes: a randomized, double-blinded and placebo-controlled clinical trial. Clin Infect Dis 2014; 58:1692.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/50\" class=\"nounderline abstract_t\">Vandenberg O, Souayah H, Mouchet F, et al. Treatment of Dientamoeba fragilis infection with paromomycin. Pediatr Infect Dis J 2007; 26:88.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/51\" class=\"nounderline abstract_t\">van Hellemond JJ, Molhoek N, Koelewijn R, et al. Is paromomycin the drug of choice for eradication of Dientamoeba fragilis in adults? Int J Parasitol Drugs Drug Resist 2012; 2:162.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/52\" class=\"nounderline abstract_t\">Kurt O, Girginkarde&#351;ler N, Balcio&#287;lu IC, et al. A comparison of metronidazole and single-dose ornidazole for the treatment of dientamoebiasis. Clin Microbiol Infect 2008; 14:601.</a></li><li><a href=\"https://www.uptodate.com/contents/dientamoeba-fragilis/abstract/53\" class=\"nounderline abstract_t\">Stark D, Roberts T, Marriott D, et al. Detection and transmission of Dientamoeba fragilis from environmental and household samples. Am J Trop Med Hyg 2012; 86:233.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5720 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H18561528\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MICROBIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">EPIDEMIOLOGY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">DIAGNOSIS</a></li><li><a href=\"#H1074648100\" id=\"outline-link-H1074648100\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">TREATMENT</a><ul><li><a href=\"#H21483355\" id=\"outline-link-H21483355\">Clinical approach</a></li><li><a href=\"#H1058301631\" id=\"outline-link-H1058301631\">Other agents</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">PREVENTION</a></li><li><a href=\"#H18561528\" id=\"outline-link-H18561528\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/5720|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/75072\" class=\"graphic graphic_figure\">- Dientamoeba fragilis life cycle</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">Approach to the patient with unexplained eosinophilia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ascariasis\" class=\"medical medical_review\">Ascariasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=blastocystis-species\" class=\"medical medical_review\">Blastocystis species</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-irritable-bowel-syndrome-in-adults\" class=\"medical medical_review\">Clinical manifestations and diagnosis of irritable bowel syndrome in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=enterobiasis-pinworm-and-trichuriasis-whipworm\" class=\"medical medical_review\">Enterobiasis (pinworm) and trichuriasis (whipworm)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cystoisospora-isospora-infections\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of Cystoisospora (Isospora) infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=giardiasis-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Giardiasis: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hookworm-infection\" class=\"medical medical_review\">Hookworm infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nonpathogenic-enteric-protozoa\" class=\"medical medical_review\">Nonpathogenic enteric protozoa</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=strongyloidiasis\" class=\"medical medical_review\">Strongyloidiasis</a></li></ul></div></div>","javascript":null}